|Bid||72.46 x 100|
|Ask||74.25 x 100|
|Day's range||74.11 - 75.64|
|52-week range||55.80 - 83.49|
|PE ratio (TTM)||12.35|
|Earnings date||27 Feb 2018|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||81.88|
The trio will have to take on drugmakers, PBMs, insurers, and pharmacy chains to bring down the high price of medicines.
Middlemen that negotiate drug discounts are under fire from drugmakers who say that secret rebates aren’t always shared with patients.
Neal Sample has been promoted from Chief Information Officer to Chief Operating Officer of Express Scripts. Prior to his time at Express Scripts, Sample had been the President of Enterprise Growth at American Express.
Investors seemed unsure which health-care stock to sell first, after today’s announcement of a medical cost-containment venture by Berkshire Hathaway (ticker:ticker::BRK.A), Amazon.com (AMZN), and JPMorgan Chase (JPM). The three firms gave few details about how they’ll try to cut their medical bills, but this morning’s selloff implied that Wall Street fears most for the profits of pharmacy businesses like Express Scripts Holding (ESRX), and health insurers like Cigna (CI) and Anthem (ANTM). It’s a good guess that the trio will start by targeting pharmacy spending and the profit margins of Express Scripts, CVS Health (CVS), and Walgreens Boots Alliance (WBA) as have other employer alliances aimed at health-care costs.
Amazon, Berkshire Hathaway and JPMorgan announce plans to partner on ways to cut health care costs and improve services for U.S. employees.
The U.S. Securities and Exchange Commission will review a dispute between Express Scripts Holding Co. and New York State Comptroller Thomas DiNapoli over his effort to force the prescription-benefits manager ...
St. Louis, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Express Scripts Holding Company (Nasdaq: ESRX) (“Express Scripts”) announced today its intention to release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018, after the market closes and will hold its quarterly conference call to discuss 2017 fourth quarter and full year financial results on Wednesday, February 28, 2018, at 8:30 a.m. eastern time (7:30 a.m. central time).
Express Scripts shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.
Small biotech firm Spark Therapeutics (ONCE) recently announced a new gene therapy that is designed to treat a rare, inherited retinal disease that can cause blindness. Approved by the FDA, Luxturna costs $425,000 per eye, or $850,000 for both
A new drug, Luxturna, literally allows blind people to see. It does it by using a virus to insert new genes into patients’ eyes. This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 a year.
The price is for Spark Therapeutics' Luxturna, approved by the FDA in December to treat a rare, inherited retinal disease that can lead to blindness.
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced three new payer programs: an outcomes-based rebate arrangement with a long-term durability measure, an innovative contracting model and a proposal to CMS under which payments for LUXTURNA™ (voretigene neparvovec-rzyl) would be made over time. Together, these initiatives aim to help ensure eligible U.S. patients have access to LUXTURNA, a one-time gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
The tax plan is designed to kick-start economic growth in part by offering new incentives for capital investment, which would allow businesses to lower their tax bills by writing off the cost of things like new machinery more quickly. The tax reform includes cuts to corporate tax rates and a cap on business deductions for debt interest payments among others. The reinsurer said on Friday it expects to write down a portion of its deferred tax asset and currently estimates that this anticipated write-down will reduce its net income by about $40 million in the period in which the tax bill is enacted.
A Relative Strength Rating upgrade for Express Scripts shows improving technical performance. Will it continue?
Express Scripts Holding Co. shares rose 4.3% in heavy Friday morning trade after the company was upgraded to outperform by Baird Equity Research. Baird also issued a $81 price target; Express Scripts shares ...
Jan.09 -- Express Scripts CEO Tim Wentworth discusses mergers and acquisitions in the healthcare industry. He speaks with Bloomberg's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.
Jan.09 -- Express Scripts CEO Tim Wentworth discusses the value of pharmacy benefit managers. He speaks with Bloomberg's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.